JPRN-UMIN000011691已完成未知
Efficacy of brimonidine for transient IOP rise after cataract surgery - Efficacy of brimonidine for transient IOP rise after cataract surgery
Hiroshima Uiversity0 个研究点目标入组 50 人开始时间: 2013年9月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients with glaucoma 2.Patients with a history of intraocular surgery past 6 momth. 3. Patients who have difficulty for IOP measurement with applanation tonometer. 4.Patients who with a history of uveitis, ocular infection, and severe dry eye. 5.Patients who are treated with steroids or any NSAIDs. 6. Patients who have cardiovascular disease, cerebrovascular disease, and hypotension. 7.patients with diabetes mellitus. 8. Patients who the investigator consider ineligible for enrolment.
研究者
相似试验
进行中（未招募）
1 期
Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration (BEACON Study)Geographic Atrophy Secondary to Age-related Macular DegenerationMedDRA version: 17.0Level: PTClassification code 10025409Term: Macular degenerationSystem Organ Class: 10015919 - Eye disordersEUCTR2013-003320-36-ITAllergan Limited320
进行中（未招募）
1 期
Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration (BEACON Study)Geographic Atrophy Secondary to Age-related Macular DegenerationMedDRA version: 20.0 Level: PT Classification code 10025409 Term: Macular degeneration System Organ Class: 10015919 - Eye disordersEUCTR2013-003320-36-DEAllergan Limited310
已完成
4 期
24-hour IOP-lowering Effect of Brimonidine 0.1%Open-angle GlaucomaOcular HypertensionNCT00457795Allergan15
已完成
2 期
Effect of Brimonidine on rosacea diseaseIRCT20161207031288N4Jarfandishan-e Navid-e Salamat (Janus) knowledge-based Company20
Unknown
2 期
Effectiveness and safety OF Brimonidine tartrate in treatment of glaucomaCTRI/2015/12/006473Sun Pharma Advanced Research Company Limited50